ArticleDiseases (Basel, Switzerland)2023

Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients Undergoing Active Anti-Neoplastic Treatments.

Abed Agbarya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.